Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sequus Pharmaceutical Inc.

Division of Johnson & Johnson

Latest From Sequus Pharmaceutical Inc.

Living with Limits: Device and Biotech Venture Capital

Lacking exits from either IPOs or acquisitions, squeezing returns out of biotech and device start-ups has become an increasingly difficult game. Many generalist VC firms have fled to the far more lucrative business of Internet and IT investing, particularly since both health care and IT have become far more technologically complex. Thus specialists have been taking over a much greater percentage of health care dealmaking, though shunning most of the high-risk biotech and device investing of the 80s and 90s. Their investments begin with a clearly defined, and sometimes pre-arranged, exit.

BioPharmaceutical Medical Device

Alza Takes Independence Road to Acquisition

Alza's acquisition by Abbott reflects, in part, Alza CEO Ernie Mario's belief in the near-impossibility of a mid-sized pharmaceutical company retaining a sustainable growing business. But Mario recognized that to get a high-value acquisition bid, he needed to do everything possible to create an independent, sustainable business. His strategy succeeded.

BioPharmaceutical Strategy

Biotech Deal-Making as Industry Barometer

Given the overriding interest among investors in liquidity, corporate dealmaking in biotech now only very rarely serves as validation for IPOs, let alone boosting stock prices. Instead, there's been a much sharper focus on the strategic value of dealmaking. It has become the means by which a company can protect the long-term value of an asset or asset base for maximum flexibility in the future.

BioPharmaceutical Strategy

Holding Our Breath for Inhale

Pulmonary delivery seems a narrow base on which to build a company; but Inhale is confident that through rigorous focus, it can construct plenty of deals on it. In the meantime, all eyes are on its insulin deal with Pfizer. That deal's success or failure--for reasons that may have nothing to do with Inhale or its technology--will either bring in partners still uncertain about the delivery system or scare them off.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • I. C Henderson, Chmn. & CEO
    Donald J Stewart, VP, Fin.
    Francis J Martin, PhD, VP, CSO
    Peter K Working, VP, R&D
  • Contact Info
  • Sequus Pharmaceutical Inc.
    Phone: (650) 323-9011
    960 Hamilton Ct.
    Menlo Park, CA 94025